A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis. - R3R01 study

River 3Renal Corporation0 个研究点目标入组 10 人开始时间: 待定最近更新: 2024年4月9日

适应症

试验速览

阶段: 2 期
状态: 招募中
发起方
入组人数: 10

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 99（—）

入选标准

•All Patients:
•1. Patient is able to communicate well with the investigator, understands and
•is willing to comply with all requirements of the study, and understands and
•signs the written informed consent form (ICF).
•2. For children to be eligible, one or both parents/legal guardians must sign a
•parental permission form which provides information contained in the ICF.
•Children capable of assent must express their willingness to participate by
•signing an assent form.
•3. If patient has received a COVID vaccination, the baseline visit must occur
•at least one week or more after the second/booster vaccination.
•4. Patients who have had active symptoms of COVID within 3 months prior to
•screening and are now asymptomatic for the last 2 weeks but have tested COVID
•PCR positive. If a patient is asymptomatic at screening but is COVID positive,
•then rescreening can occur after a minimum of two weeks.
•5. Both female patients, as well as female partners of male patients who are of
•child-bearing potential must be willing to not become pregnant for the complete
•duration of the study (>180 days) (90 days after the last dose of study
•medication).
•6. Males (including sterilized subjects) whose female partners have
•child-bearing potential, must agree to use male contraception (condoms) during
•the period from the time of signing the informed consent form (ICF) through 90
•days after the last dose of study drug. They must agree to immediately inform
•the investigator if their partner becomes pregnant during the study.
•AS Inclusion Criteria (in addition):
•7. Males and females with X-Linked AS and males and females with autosomal
•inherited AS.
•a. For countries that are enrolling pediatric patients: patients
•from age 12 years and older.
•b. For countries that are not enrolling pediatric patients: patients
•from age 18 years and older.
•8. Confirmed diagnosis of AS by genetic testing and /or kidney biopsy. For
•patients enrolled in the US who meet all inclusion and exclusion criteria but
•have not had their diagnosis confirmed by genetic testing or kidney biopsy, the
•Sponsor will provide for patient*s genetic testing.
•9. UPCR >=1.0 g/g.
•10. eGFR >= 45 mL/min/1.73m2 (using CKD-EPI equation for adults and
•Bedside Schwartz equation for children).
•11. ACEi/ARB therapy at maximum tolerated dose stable for at least 4
•weeks prior to screening. ACEi/ARB dose should remain stable over
•the course of the study.
•FSGS Inclusion Criteria (in addition):
•12. Male or female patients,
•a. For countries that are enrolling pediatric patients: 12 to 75 years old at
•the time of signing the informed consent
•b. For countries that are not enrolling pediatric patients: 18 to 75 years old
•at the time of signing the informed consent
•13. Primary FSGS (without any identifiable cause, and where the FSGS is
•confirmed by renal biopsy) or FSGS where there is documentation of a genetic
•mutation in a podocyte protein associated with FSGS.
•14. Steroid-resistance defined as failure to achieve partial or complete
另有 6 项未显示

排除标准

•All Patients:
•1. Uncontrolled diabetes mellitus as evidenced by an HbA1c >= 11%. For Germany:
•HbA1c >= 8.5%.
•2. Uncontrolled hypertension
•a. Adults: (SBP >= 180mmHg and/or DBP >= 100mmHg). For Germany: (SBP >= 140mmHg
•and/or DBP >= 100mmHg).
•b. Children: >= 95th percentile or >= 130/80 mm Hg, whichever is lower, as
•defined in Appendix 13.8.
•3. Moderate or severe hepatic impairment as per Child Pugh score (See Section
•9.5.4.7), except if (a) decreased serum albumin is directly related to the
•renal disease (resulting in a Child Pugh score of 7), and (b) no other
•Child-Pugh Score parameters are increased and (c) patient has no liver
•pathology in medical history.
•4. Presence of any active (i.e., with symptoms) and/or uncontrolled infection
•(including COVID).
•5. Presence of Human immunodeficiency virus (HIV).
•6. BMI > 40. For Germany: BMI > 35 (Obesity Class II).
•7. History of malignancy other than treated basal cell or squamous cell skin
•cancer within the past 5 years.
•8. History of alcohol abuse in the last 5 years or currently drinks in excess
•of 21 and 14 units per week for males and females, respectively.
•9. Received an investigational agent within 30 days or 5 half-lives prior to
•screening (whichever is longer).
•10. History of non-compliance such that patient is unlikely to be compliant
•with study visits, procedures or drug administration.
•11. Patient has had an organ transplant, is currently on an organ transplant
•waiting list or there is a reasonable possibility that the patient will have an
•organ transplant in the 6 months after screening.
•12. Participation in an interventional trial within the previous 3 months prior
•to screening or concurrent participation in a research trial.
•13. Patient is not suitable to participate in the study for any reason
•(including, but not limited to co-morbidities, history of non-compliance with
•study visits, procedures, or drug administration) in the opinion of the
•investigator.
•14. Females of childbearing potential (those who are not surgically sterilized
•or post-menopausal for at least 1 year) are excluded from participation in the
•study unless they agree to use highly effective contraception as described in
•Section 13.3.
•15. Females that are lactating.
•16. History of hypersensitivity to study drug and/or any of its excipients.
•17. Patients with hereditary galactose intolerance, total lactase deficiency or
•glucose-galactose malabsorption.
•18. Required concomitant use of bardoxolone, rituximab, cyclo-phosphamide,
•abatacept or sparsentan.
•AS Exclusion Criteria (in addition):
•19. Kidney disease apart from AS, e.g., diabetic nephropathy or lupus nephritis.
•20. Use of Bardoxolone or sparsentan treatment in the 30 days prior to
•screening. SGLT2 inhibitors are allowed if the patient is on a stable dose for
•at least 3 months prior to screening.
•FSGS Exclusion Criteria (in addition):
另有 7 项未显示

研究者

发起方

River 3Renal Corporation

相似试验

招募中

1 期

R3R01 in Alport Syndrome Patients and Primary Steroid-Resistant Focal Segmental GlomerulosclerosisAlport Syndrome (AS) and Primary Steroid-Resistent FocalSegmental Glomerulosclerosis (FSGS)MedDRA version: 20.0Level: PTClassification code 10001843Term: Alport's syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 21.1Level: PTClassification code 10067757Term: Focal segmental glomerulosclerosisSystem Organ Class: 10038359 - Renal and urinary disorders

EUCTR2021-004192-13-NLRiver 3 Renal, Corporation50

进行中（未招募）

1 期

EUCTR2021-004192-13-BERiver 3 Renal, Corporation50

进行中（未招募）

1 期

R3R01 in Alport Syndrome Patients and Primary Steroid-Resistant Focal Segmental Glomerulosclerosis

EUCTR2021-004192-13-FRRiver 3 Renal, Corporation50

招募中

1 期

R3R01 in Alport Syndrome Patients and Primary Steroid-Resistant Focal Segmental GlomerulosclerosisAlport Syndrome (AS) and Primary Steroid-Resistent Focal Segmental Glomerulosclerosis (FSGS)MedDRA version: 21.1Level: PTClassification code: 10067757Term: Focal segmental glomerulosclerosis Class: 100000004857MedDRA version: 20.0Level: PTClassification code: 10001843Term: Alport's syndrome Class: 100000004850

CTIS2024-512964-73-00River 3 Renal Corp.60

进行中（未招募）

1 期

Safety and effect of BL-8040 with pembrolizumab in patients with pancreatic cancerPancreatic cancer

EUCTR2018-004372-36-ESBioLineRx Ltd.80